腎デナベーションデバイス市場 - 成長率、傾向、および予測（2019年 - 2024年）
Renal Denervation Devices Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||871444|
|出版日||ページ情報||英文 114 Pages
|腎デナベーションデバイス市場 - 成長率、傾向、および予測（2019年 - 2024年） Renal Denervation Devices Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年05月01日||ページ情報: 英文 114 Pages||
The major factors for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure.
High blood pressure is called hypertension. The prevalence of hypertension has observed a significant rise over the past few years. Generally, blood pressure rises and falls throughout the day, but it can damage one's heart and result in health problems if hypertension stays high for a long time. According to the CDC (Centers for Disease Control and Prevention), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of them with high blood pressure have their condition under control. High blood pressure was a primary and contributing cause of death for more than 410,000 Americans, in 2014. CDC also states that high blood pressure costs the nation USD 48.6 billion every year. The high prevalence is not just limited to the United States, owing to the fact that Europe and South Asian countries also have a high rate of hypertension makes this a global problem. On the other hand, only a few renal denervation devices are approved in Europe, while the major players are gaining approval for the clinical trials from the FDA in the United States. Thus, owing to the all above-mentioned factors the market is expected to witness high growth in the next coming years.
As per the scope of this report, renal denervation devices are one of several innovative device-based interventional therapies, which helps to control blood pressure. It is safe, minimally invasive, and it does not leave any implants behind. The market is segmented by technology and geography.
Ultrasound-Based is the Segment by Technology is expected to be the Fastest Growing Segment
The ultrasound-based renal denervation devices is a minimally invasive procedure using ultrasound to ablate nerves in the wall of the renal arteries and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Furthermore, according to the first randomized trial to compare the techniques (RADIO SOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach led to greater reductions in the blood pressure than radiofrequency ablation in patients with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market.
Europe is Expected to Dominate the Market
Europe is found to hold a major share for the renal denervation devices market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the data published by Public Health England, high blood pressure affects more than 1 in 4 adults in England. There is a number of renal denervation devices who have received CE approval in Europe. The major factor driving the growth of the market is rising R&D activities for the development of efficient devices. As per the clinicaltrials.gov, one of the market player Abbott Medical Devices has completed the observational study of the EnligHTN renal denervation system in Europe in February 2019. Furthermore, rising cases of drug-resistant hypertension will boost the overall growth of the market over the forecast period.
The market studied is a consolidated market owing to the presence of the few major market players. Some of the market players are Abbott, Ablative Solutions, Boston Scientific Corporation, CardioSonic, Kona Medical, Medtronic Plc, Mercator MedSystems, ReCor Medical, and Symple Surgical